Oligometastatic Recurrent Ovarian Cancer Treated Using Stereotactic Body Radiotherapy

Satya NARAYAN,1 Puneet PAREEK,1 Tej Prakash SONI,2 Sweta SONI,1 Puneet BAGRI1

1Department of Radiation Oncology, AIIMS, Jodhpur-Hindistan
2Department of Radiation Oncology, Bhagwan Mahaveer Cancer Hospital & Research Centre, Jaipur-Hindistan

SUMMARY
Ovarian cancer is one of the most aggressive and frequent gynecological cancers. Despite an aggressive approach, patients often recur. The treatment options at recurrence are limited, although additional systemic therapy is usually administered. In the recent era, stereotactic body radiation therapy (SBRT) to the area(s) of the oligo-metastatic re-current disease can provide adequate tumor response with good local control. Here, we report a case of 48 years old female, diagnosed with recurrent metastatic ovarian malignancy, successfully treated with the use of SBRT. SBRT is well tolerated with low toxicity rates and effective means of oligo-metastasis control.

Keywords: Ovarian cancer; oligo-metastasis; stereotactic body radiotherapy.

Introduction
Oligo-metastatic ovarian cancer is a state of limited metastatic disease ≤3 sites that may be amenable to aggressive local therapy to gain good local control and disease-free survival. In recent radiation technology era, SBRT has become a viable treatment option for selected cases with oligo-metastatic disease. Ovarian cancer remains one of the most aggressive gynecological cancers, and the most frequent cause of death among them.[1] Patients with ovarian cancer frequently develop metastatic disease even after current standard of care treatment.

Case Report
Forty eight years old premenopausal lady with history of ovarian malignancy in 2015, treated using neo-adjuvant chemotherapy followed by debulking procedure (exploratory lapotomy with hysterectomy with bilateral salpingo-oophorectomy with infracolic omentectomy with pelvic lymphadenectomy) followed by adjuvant chemotherapy. Later, she was on regular follow up every three monthly with CA 125 and imaging-based monitoring. Approximately 14 months from the last chemotherapy, she was presented with complaints of pain abdomen and decreased appetite. On PET, CT scan showed hypodense area in segment II (3.1x3.1 cm) and segment V (2.2x2.1 cm) of the liver with the L1 vertebral lesion (SUV 8.27) and left-sided pelvic nodule (2x2 cm). The patient was planned for radiation treatment. The optimum treatment plan was generated using Rapid Arc based SBRT and doses to liver Segment II 30 Gy in six fractions. In view of >1cm motion target with respiration cycle and very close proximity (0.5 cm) to Stomach and 40Gy in five fractions in one week to L1 vertebra, SOL Liver Segment V, Left common iliac node and left pelvic nodule. Image verification was done daily with CBCT scans.

After one month of EBRT completion, she underwent two cycles of palliative chemotherapy (Nab-Pa-
stereotactic body radiotherapy (SBRT). This recent treatment delivery modality improved the biological effectiveness of radiation treatment, which means allowing the reduction of healthy tissue irradiation and increasing the total tumor dose. SBRT technology is also known as stereotactic ablative radiotherapy (SABR). In comparison to conventionally fractionated radiotherapy, which mostly involves daily doses of 1.8 to 2.0 Gy delivered over six to eight weeks, SBRT bring into effect higher doses per treatment (6-30 Gy) delivered over a shorter time frame (typically 1-5 fractions over 1-2 weeks).[2] SBRT is a linear accelerator-based focal radio-therapy delivered with the rigid patient and tumor immobilization, elegant dosimetry, and daily image guidance for verification of setting up. Consent was obtained for this case report.

Discussion

The recent advancement in radiation therapy has enabled the delivery of highly conformal, ablative doses of RT to multiple extracranial sites, known as stereotactic body radiotherapy (SBRT). This recent treatment delivery modality improved the biological effectiveness of radiation treatment, which means allowing the reduction of healthy tissue irradiation and increasing the total tumor dose. SBRT technology is also known as stereotactic ablative radiotherapy (SABR). In comparison to conventionally fractionated radiotherapy, which mostly involves daily doses of 1.8 to 2.0 Gy delivered over six to eight weeks, SBRT bring into effect higher doses per treatment (6-30 Gy) delivered over a shorter time frame (typically 1-5 fractions over 1-2 weeks).[2] SBRT is a linear accelerator-based focal radio-therapy delivered with the rigid patient and tumor immobilization, elegant dosimetry, and daily image guidance for verification of setting up. Consent was obtained for this case report.

The toxicity and tumor response was scored using the Radiation Therapy Oncology Group (RTOG)/European Organization for Research and Treatment of Cancer (EORTC) Scale. Follow-up is continuing and two years of post-chemotherapy. She still has no signs of relapse, neither on PET-CT scans (Fig. 1c) nor biochemically (CA 125 Values, Fig. 2), and she remains in excellent clinical condition. Consent was obtained for this case report.

Discussion

The recent advancement in radiation therapy has enabled the delivery of highly conformal, ablative doses of RT to multiple extracranial sites, known as stereotactic body radiotherapy (SBRT). This recent treatment delivery modality improved the biological effectiveness of radiation treatment, which means allowing the reduction of healthy tissue irradiation and increasing the total tumor dose. SBRT technology is also known as stereotactic ablative radiotherapy (SABR). In comparison to conventionally fractionated radiotherapy, which mostly involves daily doses of 1.8 to 2.0 Gy delivered over six to eight weeks, SBRT bring into effect higher doses per treatment (6-30 Gy) delivered over a shorter time frame (typically 1-5 fractions over 1-2 weeks).[2] SBRT is a linear accelerator-based focal radio-therapy delivered with the rigid patient and tumor immobilization, elegant dosimetry, and daily image guidance for verification of setting up. Consent was obtained for this case report.

Discussion

The recent advancement in radiation therapy has enabled the delivery of highly conformal, ablative doses of RT to multiple extracranial sites, known as stereotactic body radiotherapy (SBRT). This recent treatment delivery modality improved the biological effectiveness of radiation treatment, which means allowing the reduction of healthy tissue irradiation and increasing the total tumor dose. SBRT technology is also known as stereotactic ablative radiotherapy (SABR). In comparison to conventionally fractionated radiotherapy, which mostly involves daily doses of 1.8 to 2.0 Gy delivered over six to eight weeks, SBRT bring into effect higher doses per treatment (6-30 Gy) delivered over a shorter time frame (typically 1-5 fractions over 1-2 weeks).[2] SBRT is a linear accelerator-based focal radio-therapy delivered with the rigid patient and tumor immobilization, elegant dosimetry, and daily image guidance for verification of setting up. Consent was obtained for this case report.

Discussion

The recent advancement in radiation therapy has enabled the delivery of highly conformal, ablative doses of RT to multiple extracranial sites, known as stereotactic body radiotherapy (SBRT). This recent treatment delivery modality improved the biological effectiveness of radiation treatment, which means allowing the reduction of healthy tissue irradiation and increasing the total tumor dose. SBRT technology is also known as stereotactic ablative radiotherapy (SABR). In comparison to conventionally fractionated radiotherapy, which mostly involves daily doses of 1.8 to 2.0 Gy delivered over six to eight weeks, SBRT bring into effect higher doses per treatment (6-30 Gy) delivered over a shorter time frame (typically 1-5 fractions over 1-2 weeks).[2] SBRT is a linear accelerator-based focal radio-therapy delivered with the rigid patient and tumor immobilization, elegant dosimetry, and daily image guidance for verification of setting up. Consent was obtained for this case report.

Discussion

The recent advancement in radiation therapy has enabled the delivery of highly conformal, ablative doses of RT to multiple extracranial sites, known as stereotactic body radiotherapy (SBRT). This recent treatment delivery modality improved the biological effectiveness of radiation treatment, which means allowing the reduction of healthy tissue irradiation and increasing the total tumor dose. SBRT technology is also known as stereotactic ablative radiotherapy (SABR). In comparison to conventionally fractionated radiotherapy, which mostly involves daily doses of 1.8 to 2.0 Gy delivered over six to eight weeks, SBRT bring into effect higher doses per treatment (6-30 Gy) delivered over a shorter time frame (typically 1-5 fractions over 1-2 weeks).[2] SBRT is a linear accelerator-based focal radio-therapy delivered with the rigid patient and tumor immobilization, elegant dosimetry, and daily image guidance for verification of setting up. Consent was obtained for this case report.

Discussion

The recent advancement in radiation therapy has enabled the delivery of highly conformal, ablative doses of RT to multiple extracranial sites, known as stereotactic body radiotherapy (SBRT). This recent treatment delivery modality improved the biological effectiveness of radiation treatment, which means allowing the reduction of healthy tissue irradiation and increasing the total tumor dose. SBRT technology is also known as stereotactic ablative radiotherapy (SABR). In comparison to conventionally fractionated radiotherapy, which mostly involves daily doses of 1.8 to 2.0 Gy delivered over six to eight weeks, SBRT bring into effect higher doses per treatment (6-30 Gy) delivered over a shorter time frame (typically 1-5 fractions over 1-2 weeks).[2] SBRT is a linear accelerator-based focal radio-therapy delivered with the rigid patient and tumor immobilization, elegant dosimetry, and daily image guidance for verification of setting up. Consent was obtained for this case report.
rates of local control, minimal acute and late toxicities, and can be used in women who have had prior radiotherapy.

Prognosis of metastatic ovarian cancer is poor, but it is a radiosensitive disease. The use of radiation treatment in ovarian malignancy was drastically compromised due to toxicity issues. The toxicity was basically because of whole abdomino-pelvic (WAP) radiotherapy using the “moving strip” technique.[3] The compromised radiation use has partially been resolved by the development of modern techniques, i.e., stereotactic body radiotherapy (SBRT). Considering the high local control rates for oligo-metastases (70-90% at two years) and a low toxicity profile (up to less than 10% grade three toxicity) have been reported for SBRT in several types of malignancy.[4] Table 1 summarizes few studies of SBRT in the management of metastatic gynecologic malignancies have been published in the literature, including metastatic ovarian cancer.[5-7] In a Phase II study, Cleveland SBRT trial Kunos et al. treated 50 females (50% with primary ovarian cancer) with ≤4 sites of metastatic disease with SBRT to a dose 8 Gy×3 fractions using Cyber-knife. Vallow L et al. suggest that up to 5 cm. size lesion was treated by SBRT at Mayo Clinic Florida per protocol in Liver Oligometastasis in Phase I study. Common treatment sites included para-aortic nodes (38%), pelvic nodes (28%), and the liver (16%). The treatment outcome of median disease-free survival was 7.8 months and overall survival was 20.2 months, with only 3 grade ≥3 toxicities. The local control rate for abdominal lymph nodes and hepatic metastasis suggest promising results in various published studies. Here, we present a case of re-current metastatic ovarian cancer that remains disease-free with excellent performance status and less toxicity at two years after receiving SBRT.

SBRT serves to decrease tumor burden, help stimulate innate immune response or expose tumor neo-antigens and, destroy chemo-resistant tumor clones, providing excellent rates of local control with minimal

Fig. 2. CA 125 Monitoring pre and post therapy.
acute and late toxicities and can be used in patients who have had prior radiotherapy.[3]

Conclusion

Stereotactic body radiotherapy treatment is well tolerated with low toxicity rates and effective means of oligo-metastasis control. It could represent an available treatment option for oligo-metastatic patients not amenable to surgery, even when patients had been pretreated with chemotherapy.

Peer-review: Externally peer-reviewed.
Conflict of Interest: None declared.

References


<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Major Site(s) of lesion(s)</th>
<th>Number of lesions</th>
<th>Doses prescribed</th>
</tr>
</thead>
<tbody>
<tr>
<td>University of California Mesko et al.[7]</td>
<td>2017</td>
<td>Recurrent/metastatic ovarian, vaginal, cervical, endometrial cancers</td>
<td>≥1</td>
<td>Median of 8 Gy×5 fractions</td>
</tr>
<tr>
<td>J.M. Rohann et al.[6]</td>
<td>2016</td>
<td>Abdomino-pelvic LN, Liver, Lung, Para vaginal mass</td>
<td>≥1</td>
<td>Abdomino-pelvic LN 36-45 Gy/6fr, Liver 67.5-75 Gy/3fr, Lung 48 Gy/4fr, Para-vaginal mass 36 Gy/6fr Carboplatin+Gemcitabine+SBRT to 8 Gy×3 fractions</td>
</tr>
<tr>
<td>Ohio Kunos et al.[5]</td>
<td>2012</td>
<td>Metastatic sites, ovarian, primary peritoneal, endometrial cancers</td>
<td>≤4</td>
<td></td>
</tr>
</tbody>
</table>

SBRT: Stereotactic body radiation therapy